| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Black Diamond Therapeutics, Inc. (BDTX) has 6 insiders with recent SEC Form 4 filings, including 1 buy and 33 sells. BDTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 93.6K | $267.6K | - | |
| Dir | 37.1K | $106.2K | - | |
| Dir | 30.6K | $87.4K | - | |
| Dir | 30.6K | $87.4K | - | |
| Dir | 30.6K | $87.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 12, 2020 | Hatzis-Schoch Brent82 | See Remarks | Sale+OE | 4,078 | $32.70 | $133,330.93 | -39.3% | |
| Oct 12, 2020 | Bolzon Bradley J Phd75 | Director, 10% Owner | Sell | 22,625 | $33.50 | $757,923.76 | - | |
| Oct 12, 2020 | Versant Venture Capital Vi, L.P.64 | 10% Owner | Sell | 22,625 | $33.50 | $757,923.76 | - | |
| Oct 8, 2020 | Leggett Thomas | Chief Financial Officer | Sale+OE | 3,000 | $33.53 | $100,575.90 | -100% | |
| Oct 7, 2020 | Versant Venture Capital Vi, L.P.64 | 10% Owner | Sell | 45,926 | $33.44 | $1,535,732.23 | -0.3% | |
| Oct 7, 2020 | Bolzon Bradley J Phd75 | Director, 10% Owner | Sell | 45,926 | $33.44 | $1,535,732.23 | -0.3% | |
| Oct 5, 2020 | Roberts Christopher D. | Chief Scientific Officer | Sale+OE | 2,500 | $31.28 | $78,187.74 | -91.7% | |
| Oct 1, 2020 | Epstein David M. | See Remarks | Sale+OE | 12,000 | $30.33 | $363,962.40 | -1.6% | |
| Sep 30, 2020 | Ingram Robert Alexander | Director | Buy | 5,000 | $30.46 | $152,285.00 | New | |
| Sep 14, 2020 | Hatzis-Schoch Brent82 | See Remarks | Sale+OE | 4,078 | $31.04 | $126,583.04 | -27.8% |